Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19540042 | 0.88 | TSHR (0.39) | HTR2CMAOBPNMTCD44TRPA1 | |
| SCHEMBL28067377 | 0.88 | HTR2C (0.34) | HTR2CMAOBPNMTCD44TRPA1 | |
| SCHEMBL213709 | 0.78 | PARP1 (0.42) | HTR2CMAOBPNMTCD44TRPA1 | |
| SCHEMBL29696017 | 0.78 | PARP1 (0.42) | HTR2CMAOBPNMTCD44TRPA1 | |
| SCHEMBL6488209 | 0.77 | PARP1 (0.41) | HTR2CMAOBPNMTCD44TRPA1 | |
| SCHEMBL7309901 | 0.72 | PARP1 (0.37) | MAOBPNMTCD44TRPA1PARP1 | |
| Formic Acid SCHEMBL28778115 | 0.69 | PARP1 (0.35) | TRPA1PARP1 | |
| SCHEMBL19579719 | 0.67 | HTR2C (0.48) | HTR2CMAOBPNMTCD44NISCH | |
| SCHEMBL56690 | 0.67 | TRPA1 (0.42) | HTR2CMAOBTRPA1NISCHTSHR | |
| Bromide SCHEMBL7979442 | 0.65 | TRPA1 (0.41) | HTR2CMAOBTRPA1NISCHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104755473-B | 2,3 benzodiazepine * | 拜耳医药股份有限公司 | 2017-03-08 | — | — | CN | claimed |
| US-4423044-A | NERVOUS SYSTEM DISORDERS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-12-27 | — | — | US | claimed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| CN-104755473-B | 2,3 benzodiazepine * | 拜耳医药股份有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| CN-105263919-A | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines | Bayer Pharma AG | 2016-01-20 | — | — | CN | disclosed |
| EP-2958909-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015121226-A1 | 6-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| CN-104755473-A | 2,3-benzodiazepines | Bayer Pharma AG | 2015-07-01 | — | — | CN | disclosed |
| WO-2004069197-A2 | NOVEL SUBSTITUTED 2,3-BENZODIAZEPINE DERIVATIVES | IVAX CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
| EP-0726257-B1 | 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepine derivatives useful for the treatment of central nervous system disorders, and benzopyrylium intermediates for their preparation | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2001-04-11 | — | — | EP | disclosed |
| US-6075018-A | TRANQUILIZERS | EGIS GYOGYSZERGYAR RT. (HU) | 2000-06-13 | — | — | US | disclosed |
| EP-0726256-A1 | 1-Arylvinyl-3,4-dihydro-5H-2,3-benzodiazepine derivatives useful for the treatment of central nervous system disorders | EGIS GYOGYSZERGYAR RT. (HU) | 1996-08-14 | — | — | EP | disclosed |
| US-4835152-A | CENTRAL NERVOUS SYSTEM STIMULANTS | BIOGAL GYOGYSZERGYAR (HU) | 1989-05-30 | — | — | US | disclosed |
| US-4423044-A | NERVOUS SYSTEM DISORDERS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-12-27 | — | — | US | disclosed |
| US-4423044-A | NERVOUS SYSTEM DISORDERS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-12-27 | — | — | US | disclosed |
| US-4423044-A | NERVOUS SYSTEM DISORDERS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BRD4, BRDT, BICRA | HTR2C 1394/4885MAOB 3088/4885PNMT 2635/4885 |
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | GABRB2, GABRB3, GABRA2 | HTR2C 442/4885MAOB 619/4885PNMT 3113/4885 |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BRD4, BET1, BRDT | HTR2C 1475/4885MAOB 1345/4885PNMT 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.